Skip to main content

Biogen Idec, Acorda Therapeutics to develop, commercialize MS drug


CAMBRIDGE, Mass. Two drug makers have announced plans to develop and commercialize a multiple sclerosis treatment in markets outside the United States.

Biogen Idec and Acorda Therapeutics said the agreement to market Fampridine-SR (4-aminopyridine) was a sublicensing of an existing license agreement between Acorda and a subsidiary of Elan Corp. The drug is an orally administered, sustained-release drug being developed to improve walking ability in patients with MS.

Under the terms of the agreement, Biogen Idec will commercialize Fampridine-SR and other aminopyridine products in markets outside the United States, and also will have responsibility for regulatory affairs and future clinical development of the drug. In exchange, Acorda will receive an upfront payment of $110 million and additional payments of up to $400 million based on the successful achievement of future regulatory and sales milestones.

The companies said the Food and Drug Administration is reviewing a regulatory approval application for the drug for the U.S. market.

This ad will auto-close in 10 seconds